New evidence also shows that TDO is overexpressed in uveal melanoma and breast cancer, and correlates with a poor prognosis in breast cancer, which suggests that TDO may be a new target for cancer immunotherapy (Liu et al., 2020; Terai et al., 2020). Here, TDO2 is linked to uveal melanoma.